The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Open accessAbstract
Insulin-dependent diabetes may occur in patients with cancers who are treated with checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two academic institutions and identified 27 patients in whom this developed, or an incidence of 0.9%. The patients had a variety of solid-organ cancers, but all had received either anti–PD-1 or anti–PD-L1 antibodies. Diabetes presented with ketoacidosis in 59%, and 42% had evidence of pancreatitis in the peridiagnosis period. Forty percent had at least one positive autoantibody and 21% had two or more. There was a predominance of HLA-DR4, which was present in 76% of patients. Other immune adverse events were seen in 70%, and endocrine adverse events in 44%. We conclude that autoimmune, insulin-dependent diabetes occurs in close to 1% of patients treated with anti–PD-1 or –PD-L1 CPIs. This syndrome has similarities and differences compared with classic type 1 diabetes. The dominance of HLA-DR4 suggests an opportunity to identify those at highest risk of these complications and to discover insights into the mechanisms of this adverse event.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“To date, the majority of immune checkpoint inhibitor -related cases of type 1 diabetes occur in people with high-risk HLA-DR4 (present in 76% of individuals), whereas other high-risk HLA alleles are not more common than those in the general population (67).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“This immune-related adverse event occurs in just under 1% of checkpoint inhibitor -treated individuals but most commonly occurs with agents that block the programmed cell death protein 1/programmed cell death ligand 1 pathway alone or in combination with other checkpoint inhibitors (67).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [67]
The cited source says what the claim attributes to it.
In the citing paper
“This immune-related adverse event occurs in just under 1% of checkpoint inhibitortreated individuals but most commonly occurs with agents that block the programmed cell death protein 1/programmed cell death ligand 1 pathway alone or in combination with other checkpoint inhibitors (66).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“A new and emerging issue is the development of profound insulin deficiency associated with the use of immune check-point inhibitors, which may present with hyperglycemia and diabetic ketoacidosis (DKA) (4).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is still unclear if steroid-sparing regimens decrease the risk of PTDM with studies showing mixed results.1591–1595”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1593]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
Chen, L., & Han, X. N. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80011 · Cited by 1,455
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,220
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function
Pescovitz, M. D., Greenbaum, C. J., Krause-Steinrauf, H., Becker, D. J., Gitelman, S. E., Goland, R., Gottlieb, P. A., Marks, J. B., McGee, P. F., Moran, A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904452 · Cited by 1,093
The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice
Ansari, M. J., Salama, A. D., Chitnis, T., Smith, R. N., Yagita∥, H., Akiba, H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S. J., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022125 · Cited by 817
Flagged first, then by citations
1 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Alzenaidi, 2017, Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma, J La State Med Soc, 169, 49
Cited by
Sorted by citations
Items 401–500 of 594
Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature
Marsiglio, J., McPherson, J. P., Wahl, M., & Hu‐Lieskovan, S. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000000998 · Cited by 3
Immune checkpoint inhibitor-associated diabetes mellitus: the case series report
Ma, Y., Xue, J., Cheng, Q., Qian, H., & Du, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1589630 · Cited by 3
Qi, R., Xu, H., Fu, X., Yu, Y., Lv, D., Li, Y., & He, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1046266 · Cited by 3
SARS-CoV-2-Vaccine-Related Endocrine Disorders: An Updated Narrative Review
Ishay, A., Oleinikov, K., & Shacham, E. C. (2024) · Vaccines · doi:10.3390/vaccines12070750 · Cited by 3
Immune Checkpoint Inhibitor-Induced Diabetes Mellitus—A Brief Review and Three Case Reports
Mitrache, M.-L., Reghina, A. D., Stoian, I.-S., & Fica, S. V. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186620 · Cited by 3
Fujiwara, N., Watanabe, M., Katayama, A., Noda, Y., Eguchi, J., Kataoka, H. U., Kagawa, S., & Wada, J. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4574 · Cited by 3
Zheng, Z., Wang, J.-L., Li, W.-X., Wu, T., Chen, M., & Zhou, Z.-G. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.917679 · Cited by 3
Toripalimab-associated diabetes mellitus: a case report from the community of Southern China
Zhang, W., & Xu, W. (2023) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-22-0387 · Cited by 3
Sintilimab-related diabetes mellitus and psoriasis: A case report and literature review
Huang, W., Liu, Y., Li, M., Xue, Y., Bao, W., & Guo, Y. (2023) · Medicine · doi:10.1097/md.0000000000035946 · Cited by 3
There Is Something About Insulin Granules
Roep, B. O. (2020) · Diabetes · doi:10.2337/dbi20-0039 · Cited by 3
The impact of the COVID-19 pandemic on diabetic ketoacidosis admissions to a COVID-19-free hospital
Alnuaimi, M., Siddiqua, A. R., Aljaberi, A. K., Alkaabi, J., Aldahmani, K. M., Afandi, B. O., & Almazrouei, R. A. (2021) · Journal of Diabetes and Endocrine Practice · doi:10.4103/jdep.jdep_45_21 · Cited by 3
Hypoglycemia as first presentation of presumed immune checkpoint inhibitor‐induced type 1 diabetes
Kamal, R. S., Dean, A., Dutt, H., Rajeh, A., & Fernandes, R. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7897 · Cited by 3
Immune Checkpoint Inhibitor–Induced Type 1 Diabetes: An Underestimated Risk
Aktürk, H. K., & Michels, A. W. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.12.009 · Cited by 3
Pembrolizumab autoimmune related diabetes: Moving forward, keep learning
García, J., Alcaraz, D., Holgado, E., & Couñago, F. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i5.576 · Cited by 3
Aktürk, H. K., & Michels, A. W. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2024.6473 · Cited by 2
Sakaue, T., Obata, Y., Sakai, K., Onishi, A., Mukai, K., Miyashita, K., Kozawa, J., Nishizawa, H., & Shimomura, I. (2025) · Diabetology International · doi:10.1007/s13340-025-00795-0 · Cited by 2
Matsuda, T., Osaki, Y., Sekiya, M., & Shimano, H. (2025) · Journal of Rural Medicine · doi:10.2185/jrm.2024-030 · Cited by 2
The Current and Future of Biomarkers of Immune Related Adverse Events
Bracamonte‐Baran, W., & Kim, S. T. (2025) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2025.01.010 · Cited by 2
Glycemic management in patients with immune-related diabetes mellitus: A scoping review
Jiang, Y., Wang, X., Lei, L., Liu, L., Wu, D., Zhang, S., Tang, D., Fan, L., Zhou, W., Xue, X., et al. (2025) · SAGE Open Medicine · doi:10.1177/20503121251358313 · Cited by 2
Janulevicius, T., Nguyen, J., & Briggs, E. J. N. (2025) · Cureus · doi:10.7759/cureus.90424 · Cited by 2
Cadogan, S., Doherty, S., Kelly, D., & Glynn, N. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.08.014 · Cited by 2
Zou, Y., Li, Q., Zhou, L., Lu, Y., Hua, W., Zhou, Y., Lin, S., Guo, X., Yan, S., Wang, H., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1684475 · Cited by 2
Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review
Kośmider, K., Kozakiewicz, A., Krawczyk, P. A., Kieszko, R., Szklener, K., Skórzewska, M., Wojas‐Krawczyk, K., Kalinka‐Warzocha, E., & Milanowski, J. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s548443 · Cited by 2
Tan, S., Wang, Y., Cai, Y., Guo, H., & Gao, Y. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2638068 · Cited by 2
Beta cell–targeted PD-1 agonist inhibits cell-mediated autoimmunity in pancreas tissue slices
Becker, M. W., Brown, M. E., Wiseman, K., Chiodetti, A. L., Huber, M. K., Cuaycal, A. E., Sintara, P., Ferreira, S. M., Smurlick, D., Barra, J. M., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec9029 · Cited by 2
Ardeshir‐Larijani, F., Ashrafian, L., Chiappetta, M., Mansilla, D., Mariani, A. W., Menis, J., Rimner, A., Sharma, A., Szołkowska, M., Upadhya, S., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103611 · Cited by 2
An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition
Naidoo, J., Dykema, A. G., & D’Alessio, F. R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci125800 · Cited by 2
Immune checkpoint inhibitors and diabetes
Campbell, N., & Poole, R. (2020) · Practical Diabetes · doi:10.1002/pdi.2276 · Cited by 2
Beachler, D. C., Lamy, F.-X., Kolitsopoulos, F. M., Dinh, J., Papazian, A., Jamal‐Allial, A., Mahmoudpour, S. H., Michelon, E., & Verpillat, P. (2022) · Future Oncology · doi:10.2217/fon-2022-0308 · Cited by 2
Zherebchikova, K., Sych, Y. P., Amosova, M., Sekacheva, M. I., Fadeev, V. V., & Vilenskiy, A. A. (2022) · Russian Medical Inquiry · doi:10.32364/2587-6821-2022-6-9-528-533 · Cited by 2
Abrupt-onset diabetes mellitus secondary to pembrolizumab
Alcaraz, A. P., Marín-Martínez, L., Kyriakos, G., Martín, M. C. Á., & Alonso, E. H. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2022.06.013 · Cited by 2
Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2023)
Lechleitner, M., Kaser, S., Hoppichler, F., Roden, M., Weitgasser, R., Ludvik, B. H., Fasching, P., Winhofer, Y., Kautzky‐Willer, A., Schernthaner, G., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02182-8 · Cited by 2
Nguyen, T.-V., Kim, L. T., Lin, Q., Nagahara, M., Namula, Z., Wittayarat, M., Hirata, M., Otoi, T., & Tanihara, F. (2024) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-024-00869-4 · Cited by 2
Kudo, S., Yokoo, K., Tanaka, N., Yamada, G., & Kitamura, Y. (2024) · Cureus · doi:10.7759/cureus.56302 · Cited by 2
Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer
Lin, M., Bai, L., Yeh, S.-P., Chiu, C., & Lien, M.-Y. (2024) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-23-00025 · Cited by 2
Pacichana, J. A., Osorio-Toro, L. M., Restrepo-Erazo, K., Ramos, A. F. G., Tafurt, G. P. R., & Liscano, Y. (2024) · Diabetology · doi:10.3390/diabetology5060043 · Cited by 2
Minami, H., Matsukane, R., Yasukochi, S., Hirota, T., & Uchida, M. (2025) · JCO Oncology Practice · doi:10.1200/op-24-01032 · Cited by 2
Ji, P., Zhang, Y., Zhang, W., Leng, B., Nie, R., Shen, C., & Yu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1499796 · Cited by 2
Raphael, R., Nafees, S., Ravikumar, A., Nair, K., Riasat, M. H., Leonard, E., & Akbar, S. (2025) · Cureus · doi:10.7759/cureus.90999 · Cited by 2
Shavit, M. (2025) · Cureus · doi:10.7759/cureus.92247 · Cited by 2
Gao, Y., Lin, M., & Deng, J. (2025) · Medicine · doi:10.1097/md.0000000000045414 · Cited by 2
Physical development of newborns born to mothers with different carbohydrate metabolism disorders
Харитонова, Л. А., Папышева, О. В., Васильевна, Б. Л., & Bogomaz, D. S. (2019) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-161-1-88-98 · Cited by 2
Feng, C., Kibrik, P., Castañeda, C., & Singh, G. (2021) · Osteopathic Family Physician · doi:10.33181/13037 · Cited by 2
Pembrolizumab-Induced Type 1 Diabetes in a 95-Year-Old Veteran With Metastatic Melanoma
Ng, D. (2021) · Federal Practitioner · doi:10.12788/fp.0191 · Cited by 2
Bazzi, T., Gupta, E., Mohamed, A. S., & Vashi, M. (2022) · Cureus · doi:10.7759/cureus.29537 · Cited by 2
Nishihama, K., Okano, Y., Inoue, C., Maki, K., Eguchi, K., Tanaka, S., Takeshita, A., Uemura, M., Yasuma, T., Suzuki, T., et al. (2024) · Diabetology International · doi:10.1007/s13340-024-00703-y · Cited by 2
Obata, Y., Takemoto, M., Sakaue, T., Kawata, S., Mukai, K., Miyashita, K., Kozawa, J., Nishizawa, H., & Shimomura, I. (2024) · Diabetology International · doi:10.1007/s13340-024-00719-4 · Cited by 2
Arecco, A., Petolicchio, C., Pastorino, A., Tanda, E. T., Vera, L., Boschetti, M., Cocchiara, F., Maggi, D. C., Ferone, D., & Gatto, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1550702 · Cited by 2
Pancreatic islet organoids and organoids on-chip for type 1 diabetes
Mehanović, M., Lopes, M., Coffy, S., Pitaval, A., Freida, D., Gidrol, X., & Tubbs, E. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104302 · Cited by 2
Xiao, P., Zhang, L., Wang, Y., Meng, F., Wang, X., & Zhong, D. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.10 · Cited by 2
Pembrolizumab and diabetes: a case of diabetic ketoacidosis in a patient with metastatic melanoma
Lolomari, S. J., Thayyil, S., & Kong, M. (2023) · British Journal of Diabetes · doi:10.15277/bjd.2023.410 · Cited by 2
Ramburuth, V., & Rajkanna, J. (2023) · Cureus · doi:10.7759/cureus.46985 · Cited by 2
The Double-Edged Sword of Immunotherapy—Durvalumab-Induced Polyendocrinopathy—Case Report
Błażowska, O., Stróżna, K., Dancewicz, H., Zygmunciak, P., Zgliczyński, W., & Mrozikiewicz‐Rakowska, B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216322 · Cited by 2
Komiyama, S., Numata, K., Ogushi, K., Chuma, M., Tanaka, R. J., Chiba, S., Otani, M., Inayama, Y., Nakano, M., & Maeda, S. (2021) · Diagnostics · doi:10.3390/diagnostics11081394 · Cited by 2
Adverse Events Associated With Immune Checkpoint Inhibitors—Reply
Johnson, D. B., Chandra, S., & Sosman, J. A. (2019) · JAMA · doi:10.1001/jama.2018.22123 · Cited by 2
Chamberlain, C. E., German, M. S., Philipson, L. H., & Anderson, M. S. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041601 · Cited by 3
Self-citationWémeau, J.-L., BERTAGNA, X. Y., & Boîtard, C. (2018) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30188-8 · Cited by 1
Duvalyan, E., Brondfield, S., Rushakoff, R. J., Anderson, M. S., & Quandt, Z. (2024) · Cancers · doi:10.3390/cancers16091663 · Cited by 1
Self-citationLi, Z., Han, K., Li, L., Han, X., Zhang, F., & Guo, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1642893 · Cited by 1
Lin, M., Ye, R., Jhou, H., Chen, H., Kao, L., Hsieh, T. Y. J., Chen, Y., Sun, A. Y.-E., Zhang, X., Dai, M., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01940-0 · Cited by 1
Nur, A. M., & Aamir, M. (2025) · Cureus · doi:10.7759/cureus.94583 · Cited by 1
Tislelizumab-induced fulminant type 1 diabetes mellitus (FT1D): A case report and literature review
Zhou, X., Peng, J. C., Chen, M., & Chen, J. (2025) · Medicine · doi:10.1097/md.0000000000046310 · Cited by 1
Inflammation and Oxidative Stress: Common Pathways in Diabetes and Cancer
Murali, U., Muthuvel, R., Min, Y., & Subbaraj, G. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-5651-9_3 · Cited by 1
Feng, Y., Cheng, X., Liu, J., Qi, J., & Han, L. (2026) · Journal of Medical Case Reports · doi:10.1186/s13256-026-05837-y · Cited by 1
Zhao, X., Sun, X., Ma, M., Teng, L., & Qu, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1751155 · Cited by 1
Vengilote, R., Onwudiwe, O., Yousef, A., & Quartuccio, M. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag024 · Cited by 1
Hu, Q. Z., Fan, Y., & He, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1669492 · Cited by 1
Li, Y., Wang, H., Xing, G., Guo, X., & Yi, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1708071 · Cited by 1
Apurva, Chaudhary, P., & Bahuguna, S. (2026) · Current Cancer Therapy Reviews · doi:10.2174/0115733947414188251210123952 · Cited by 1
Nova, D., Pagliari, G. G., Mambrito, S., Cortinovis, D. L., & Canova, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1874841 · Cited by 1
Lekić, I., Marczi, S., Stević, M. S., Nešković, N., Tokić, S., Marušić, R., Bugarin, A., Petřek, M., & Bačun, T. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1928474 · Cited by 1
Immune Checkpoint Inhibitor-Induced Diabetes Presenting As Diabetic Ketoacidosis: A Case Report
Yadav, R., Kugavarathan, K., John, V., Lama, K., & Waziri, Y. (2026) · Cureus · doi:10.7759/cureus.114106 · Cited by 1
Zheng, L., Yang, J., Chen, X., Li, L., & Sun, J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231163807 · Cited by 1
Treatment of facial lipodystrophy induced by a biologic agent (IPD-1): a literature review
Friedhofer, H., Camargo, C. P., Oshiro, L. H., Valente, D. D. A. R., & Gemperli, R. (2024) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2024rc1111 · Cited by 1
Diabetes und onkologische Immuntherapien: Schwerer Autoimmundiabetes durch Immuntherapien möglich
Brandenburg, T., Klose, J. M., Feldkamp, J., & Tan, S. (2025) · Deutsches Ärzteblatt · doi:10.3238/personko.2025.02.07.02 · Cited by 1
Jiao, J., Li, Z., Zhu, X., Chen, L., & Wu, Y. (2025) · Endocrine Connections · doi:10.1530/ec-25-0123 · Cited by 1
Zambrano, C. B., Nogués, X., Ramírez-Merino, N., Librizzi, M. S., Castañeda, S., Etxebarría-Foronda, Í., Henao, F., Puente, J., Gurruchaga, I., & Diaz‐Guerra, G. M. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04256-1 · Cited by 1
Immune Checkpoint Inhibitor-Associated Diabetes Mellitus: Future Perspectives and Emerging Therapies
Karavendzas, J.-L., Galligan, A., Lee, M. H., DOWLING, A. J., Krishnamurthy, B., & MacIsaac, R. J. (2026) · Endocrines · doi:10.3390/endocrines7020018 · Cited by 1
Zhou, X., Huang, C., Ou, K., Xiao, S., Wang, J., & Zhang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1800914 · Cited by 1
Guo, J., Hu, Y., Liu, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1947327 · Cited by 1
Xiang, M., Liu, S., Xiao, D., & Tao, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02810-5 · Cited by 1
Simultaneous immune checkpoint blockade-associated diabetes mellitus and thyrotoxicosis
Lin, M., Franke, M., & Kudva, Y. C. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag241 · Cited by 1
Immunotherapy for Infectious Diseases, Cancer, and Autoimmunity
Krause, P. J., Kavathas, P., & Ruddle, N. H. (2019) · Springer eBooks · doi:10.1007/978-3-030-25553-4_16 · Cited by 1
Орлова, Р. В., Zhukova, N. V., Malkova, A. M., & Shoenfeld, Y. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100529 · Cited by 1
Diabetes mellitus geïnduceerd door immuuntherapie: een casus
Dekock, T., Taelman, T., Vanhaverbeke, G., Derijcke, S., & Ghysen, K. (2024) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.132 · Cited by 1
Pyronneau, A., Noronha, K., Zucker, A., Kennett, R., & Desai, P. A. (2024) · Cureus · doi:10.7759/cureus.60565 · Cited by 1
A Curious Case of Diabetic Ketoacidosis Secondary to Avelumab
Costa, M., & Magalhães, H. (2024) · Cureus · doi:10.7759/cureus.62240 · Cited by 1
8099 Pembrolizumab Induced Autoimmune Diabetes: An Abrupt Virulent Onset
Belal, H., Shaykh, N., Rajesh, A., & Chehade, J. M. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae163.878 · Cited by 1
Hallak, F., Charbonne, G., Worley, C., & McDonald, S. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.06.004 · Cited by 1
Development of type 1 diabetes mellitus after nivolumab dose escalation: A case report
Mabuchi, S., Adachi, N., Nagasawa, A., & Nabika, S. (2025) · Medicine · doi:10.1097/md.0000000000043356 · Cited by 1
Supplying Insulin while Evading Immunity
Butler, P. C. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2028410 · Cited by 1
A Case of Unexpected Hyperglycemia
Fatica, E. M., Larkey, N. E., Gleue, C. A., & Willrich, M. A. V. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab089 · Cited by 1
[Immune Checkpoint Inhibitors Related Diabetes Mellitus: A Report of 2 Cases and Literature Review].
Ren, Y., Zhang, L., Wang, Y., & Zhong, D. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.102.54 · Cited by 1
François, S., Lakomy, D., & Fabien, N. (2022) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(22)00179-4 · Cited by 1
Kaur, K. K. (2020) · Open Access Journal of Endocrinology · doi:10.23880/oaje-16000149 · Cited by 1
Varghese, J. M., & Best, C. J. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_4 · Cited by 1
Bánhegyi, R. J., Veréb, B., Gazdag, A., Rácz, B., Wagner, R. J., Fülöp, N., & Pikó, B. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32635 · Cited by 1
A Practical Approach to the Diagnosis of Type 1 Diabetes
Kumaran, S., Lalvani, N., Jevalikar, G., Sarda, A., & Unnikrishnan, A. G. (2023) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_19_22 · Cited by 1
Endocrine and Neurological Toxicities of Immunotherapies
Boydell, E., & Fernández, E. (2023) · Praxis · doi:10.1024/1661-8157/a003978 · Cited by 1
How Should Secondary Causes of Diabetes Be Excluded?
Griffin, T. P., O’Loughlin, A., & Dinneen, S. F. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch4 · Cited by 2
Metadata
- Authors
- Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., Lee, J., Bluestone, J. A., Anderson, M., & Herold, K. C.
- Affiliations
- Yale University (US)
- University of California, San Francisco (US)
- Corresponding author
- Herold, Kevan C.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-06-24
- Volume
- 67
- Issue
- 8
- Pages
- 1471-1480
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC6054443
- OpenAlex
- W2808896902
- Cited by
- 590
- References
- 51
- Citations by year
- 2026: 41 · 2025: 75 · 2024: 76 · 2023: 90 · 2022: 80 · 2021: 92 · 2020: 69 · 2019: 52 · 2018: 14
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK057846, UC4 DK116290)
- Leona M. and Harry B. Helmsley Charitable Trust (2018PG-T1D059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint inhibitors, type 1 diabetes, anti-PD-1, PD-L1 inhibitors, immune-related adverse events, ketoacidosis, pancreatitis, autoantibodies, HLA-DR4, solid organ cancer, endocrine adverse events
- MeSH terms
- Antineoplastic Agents, Immunological, Insulin Secretion, Animals, Autoimmune Diseases, Diabetes Mellitus, Type 1, Genotype, Humans, Hypoglycemic Agents, Insulin, Isoantibodies, Ketosis, Neoplasms, Pancreas, Pancreatitis, HLA-DR4 Antigen, Models, Immunological, Genetic Predisposition to Disease, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
